Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by MoriaDwarfon Sep 21, 2016 2:48pm
85 Views
Post# 25261929

RE:RE:RE:RE:Dundee Director on Gen board is good news

RE:RE:RE:RE:Dundee Director on Gen board is good news
LithLover wrote:
There are also some key mistakes that many new companies make that Gen did not. Gen's PP had 1/4 warrants not full warrants. 4 month freeze on the PP stock. That's what experience does. They don't get so excited about the cash that they give away their future. Again, that was my point. The company now has a fully functioning lab worth millions, a 3 year agreement and still only valued at $18 million. Meanwhile, EXAS is at $2 billion and if you want a crazy moonshot goal how about DGX at $11 billion.


Thank you very much PBay and LithLover, Your posts clarified everything. Sorry for my late feedback, but I'm in Bialowieza, Poland, celebrating the official opening of Fall. As Polo 11 predicted a couple of weeks ago, GEN is paying for my trip...  Good luck to all GEN longs!
Bullboard Posts